Promising Outcomes from BridgeBio Pharma’s Clinical Trials: Effective Treatments for Achondroplasia and Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma is making significant strides in addressing rare genetic conditions, evidenced by the promising results from its ongoing clinical trials. Recent announcements underscore the company’s commitment to providing effective treatments for conditions such as achondroplasia and transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting both durable therapeutic benefits and robust safety profiles.
Positive Results for Infigratinib in Achondroplasia
BridgeBio announced encouraging results from its Phase 2 PROPEL 2 trial, focusing on the Cohort 5 subgroup treated with oral infigratinib for achondroplasia. Achondroplasia is a genetic disorder characterized by dwarfism and skeletal abnormalities. The condition has limited treatment options, making these findings particularly notable.
In Cohort 5, consisting of patients receiving infigratinib at a dose of 0.25 mg/kg/day, a statistically significant and sustained increase in annualized height velocity (AHV) was observed. At Month 12, the mean change from baseline in AHV was +2.51 cm/yr, which remained consistent at +2.50 cm/yr by Month 18 (p=0.0015). These results highlight the potential of infigratinib to significantly impact growth rates in children with achondroplasia, offering a potential new standard of care.
Moreover, the company’s commitment to broader genetic growth disorders is underscored by the initiation of the ACCEL study for hypochondroplasia. This condition is related to, but distinct from, achondroplasia and represents another critical area of unmet need in pediatric endocrinology.
Phase 3 ATTRibute-CM Study for ATTR-CM Shows Promising Cardiac Outcomes
BridgeBio’s efforts extend beyond genetic growth disorders to cardiac conditions such as transthyretin amyloid cardiomyopathy (ATTR-CM). At the recent ESC-HF conference, BridgeBio presented additional data and analyses from its Phase 3 ATTRibute-CM study, highlighting the efficacy of acoramidis, an investigative treatment for ATTR-CM.
In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis of the entire intention-to-treat (ITT) population (N=632), the treatment with acoramidis resulted in a significant reduction in all-cause mortality (p=0.04). Importantly, no new safety signals of potential clinical concern were identified, reinforcing the potential of acoramidis as a viable treatment option for patients with ATTR-CM.
Further reinforcing these findings, a cardiac magnetic resonance (CMR) imaging substudy indicated that treatment with acoramidis might be associated with structural and functional cardiac improvements. Patients treated with acoramidis showed potential cardiac amyloid regression compared to those receiving placebo, signifying a possible beneficial impact on the heart’s architecture and function.
Conclusion
BridgeBio Pharma’s latest clinical trial results bring hope to patients suffering from rare genetic conditions, with infigratinib showing effectiveness in increasing growth rates in children with achondroplasia and acoramidis demonstrating potential benefits for patients with transthyretin amyloid cardiomyopathy. These advancements not only highlight the therapeutic promise of BridgeBio’s pipeline but also reiterate the importance of innovation in the development of treatments for rare and often underserved conditions.
Comments